Cargando…

The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients

In alpha-1-antitrypsin deficiency (AATD), neutrophil serine proteases such as elastase and proteinase 3 (PR3) are insufficiently inhibited. A previous study in AATD patients showed a higher plasma level of the specific PR3-generated fibrinogen-derived peptide AαVal541, compared with healthy controls...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schouten, Iris G. M., Mumford, Richard A., Moes, Dirk Jan A. R., Hiemstra, Pieter S., Stolk, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347723/ https://www.ncbi.nlm.nih.gov/pubmed/34360796 http://dx.doi.org/10.3390/ijms22158031

Ejemplares similares

Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency
por: Stolk, Jan, et al.
Publicado: (2005)

Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency
por: Buck, Emanuel, et al.
Publicado: (2022)

Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches
por: Viglio, Simona, et al.
Publicado: (2021)

Correction: Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency
por: Stolk, Jan, et al.
Publicado: (2006)

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences
por: Fregonese, Laura, et al.
Publicado: (2008)

Alpha(1)-antitrypsin deficiency: current perspective on research, diagnosis, and management
por: Stolk, Jan, et al.
Publicado: (2006)

The Relationship between Plasma Alpha-1-Antitrypsin Polymers and Lung or Liver Function in ZZ Alpha-1-Antitrypsin-Deficient Patients
por: Sark, Annelot D., et al.
Publicado: (2022)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

A specific proteinase 3 activity footprint in α(1)-antitrypsin deficiency
por: Newby, Paul R., et al.
Publicado: (2019)

Regional lung densities in alpha-1 antitrypsin deficiency compared to predicted values
por: Stoel, Berend C., et al.
Publicado: (2019)

Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History
por: Viglio, Simona, et al.
Publicado: (2020)

Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database
por: Schouten, Iris G.M., et al.
Publicado: (2021)

Does Augmentation with Alpha1-Antitrypsin Affect Neutrophil Extracellular Traps Formation?
por: Frenzel, Eileen, et al.
Publicado: (2012)

Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry
por: Stockley, Robert A, et al.
Publicado: (2010)

Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature
por: Parr, David G, et al.
Publicado: (2017)

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
por: Blanco, Ignacio, et al.
Publicado: (2011)

Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential
por: Feitosa, Paulo Henrique
Publicado: (2023)

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank
por: Tonelli, Adriano R, et al.
Publicado: (2009)

Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α(1)-antitrypsin
por: van ‘t Wout, Emily F.A., et al.
Publicado: (2014)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010)

Identification and ranking of recurrent neo-epitopes in cancer
por: Blanc, Eric, et al.
Publicado: (2019)

Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients ‘on’ or ‘off’ augmentation therapy
por: Olfert, I Mark, et al.
Publicado: (2014)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Structural characterization and conformational dynamics of alpha-1 antitrypsin pathogenic variants causing alpha-1-antitrypsin deficiency
por: Shaik, Noor Ahmad, et al.
Publicado: (2022)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

Zoophycos macroevolution since 541 Ma
por: Zhang, Li-Jun, et al.
Publicado: (2015)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
por: Hawkins, Padraig, et al.
Publicado: (2021)

Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases
Publicado: (1988)

Polymerization of misfolded Z alpha-1 antitrypsin protein lowers CX3CR1 expression in human PBMCs
por: Tumpara, Srinu, et al.
Publicado: (2021)

Implications of a Change of Paradigm in Alpha1 Antitrypsin Deficiency Augmentation Therapy: From Biochemical to Clinical Efficacy
por: López-Campos, José Luis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qsamnqp81u3q1r7eqafa3c89ha